Ad
related to: metformin and lipodystrophy drug study chart for patients men over 50
Search results
Results from the WOW.Com Content Network
A 24-week, multinational, randomized, blinded, active-controlled study (study identifier: LG-DPCL006; ClinicalTrials.gov registration number: NCT01602003) was designed to assess the efficacy and safety of gemigliptin 50 mg compared to the active control (sitagliptin) added to ongoing metformin therapy in patients with T2DM inadequately ...
Metformin was first described in scientific literature in 1922 by Emil Werner and James Bell. [29] French physician Jean Sterne began the study in humans in the 1950s. [29] It was introduced as a medication in France in 1957. [16] [30] It is on the World Health Organization's List of Essential Medicines. [31] It is available as a generic ...
Endocrinology. Lipodystrophy syndromes are a group of genetic or acquired disorders in which the body is unable to produce and maintain healthy fat tissue. [1][2] The medical condition is characterized by abnormal or degenerative conditions of the body's adipose tissue. A more specific term, lipoatrophy (from Greek lipo 'fat' and dystrophy ...
So, for example, the best time to take metformin 500mg once a day would be after your dinner. Depending on which type of metformin you take and your dose, however, you may take metformin more than ...
Metabolic syndrome is a clustering of at least three of the following five medical conditions: abdominal obesity, high blood pressure, high blood sugar, high serum triglycerides, and low serum high-density lipoprotein (HDL). Metabolic syndrome is associated with the risk of developing cardiovascular disease and type 2 diabetes. [1]
Alpha-glucosidase inhibitor. Alpha-glucosidase inhibitors (AGIs) are oral anti-diabetic drugs used for diabetes mellitus type 2 that work by preventing the digestion of carbohydrates (such as starch and table sugar). Carbohydrates are normally converted into simple sugars (monosaccharides) by alpha-glucosidase enzymes present on cells lining ...
Lipid-lowering agent. Lipid-lowering agents, also sometimes referred to as hypolipidemic agents, cholesterol-lowering drugs, or antihyperlipidemic agents are a diverse group of pharmaceuticals that are used to lower the level of lipids and lipoproteins, such as cholesterol, in the blood (hyperlipidemia).
AKITA mice are used to test drugs targeting endoplasmic reticulum stress reduction, to test islet transplants, and to study diabetes-related complications such as nephropathy, sympathetic autonomic neuropathy, and vascular disease. [144] [152] for testing transplantation therapies. Their advantage is mainly the low cost, the disadvantage is the ...
Ad
related to: metformin and lipodystrophy drug study chart for patients men over 50